@2024 - All Right Reserved.
INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- New36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and weight ...
Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback